Drugs / RN0361
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06471543 | Sep 2024 → Jun 2026 overdue | familial chylomicronemia syndrome, hypertriglyceridemia | Ikaria Bioscience Pty Ltd | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Shanghai Rona Therapeutics Co., Ltd. | Results Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions ronatherapeutics.com ↗ |
| 2025-03-17 | Shanghai Rona Therapeutics Co., Ltd. | Regulatory Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia ronatherapeutics.com ↗ |
| 2024-07-26 | Shanghai Rona Therapeutics Co., Ltd. | Regulatory Rona Therapeutics announced that the self-developed APOC3 siRNA drug， RN0361，received approval for a Phase I clinical trial application in Australia ronatherapeutics.com ↗
On July 26th, 2024, Rona Therapeutics announced that its Investigational New Drug (IND) application for its potentially Best-in-Class siRNA pipeline product, RN0361, has been approved in Australia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions ronatherapeutics.com ↗ |
| 2025-03-17 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia ronatherapeutics.com ↗ |
| 2024-07-26 | Shanghai Rona Therapeutics Co., Ltd. | Rona Therapeutics announced that the self-developed APOC3 siRNA drug， RN0361，received approval for a Phase I clinical trial application in Australia ronatherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN0361 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06471543 ↗ |
| Route | Subcutaneous | “subcutaneous injections” NCT06471543 ↗ |